Gentle physical stimulation during blood cancer transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a low-intensity mechanical (physical) stimulation is safe and helpful for people with certain blood cancers who are about to have a transplant. It may affect how you do during or after treatment, and participation is voluntary with informed consent.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You are scheduled for a planned stem cell transplant (autologous or allogeneic)
- If you are in the second group, you have a qualifying non-Hodgkin lymphoma type (or CLL)
- You must be able and willing to follow the study plan and attend required visits or procedures
- You must sign a written consent form after understanding this is an experimental study
- Your weight must be under 275 pounds and your BMI must be at least 18
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Hear when a new Hematopoietic and Lymphoid System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.